Table 3.

Targeted therapies that directly target the aberrant chromatin remodelers as anticancer agents.

Directly Targets	Associated Cancers	Directly Targeted Agents
SMARCA4 and SMARCA2	Glioblastoma	PFI-3 targets the essential bromodomain and blocks SWI/SNF’s chromatin binding [167,168].
SMARCA2 and SMARCA4	SMARCA4-deficient lung-cancer; uveal melanoma	A dual allosteric small-molecule inhibitor targets ATPase activity of SMARCA2 and SMARCA4 [169].
SMARCA2 and SMARCA4	AR/FOXA1-driven prostate cancer	AU-15330 is a proteolysis-targeting chimera degrader of the SMARCA2 and SMARCA4 [170].
SMARCA2 and SMARCA4	SMARCA4-mutant lung cancer	SMASh degron-mediated SMARCA2 depletion [171].
SMARCA2, SMARCA4, and PBRM1	Unknown	GNE-064 is a chemical probe targeting the bromodomains SMARCA2, SMARCA4, and PBRM1 [172].
PBAF complex	Unknown	LM146 targets the PBAF complex component by blocking the specific bromodomains within the complex [173].
BRD7/9	Unknown	Compounds LP99 is selective inhibitor of the BRD7 and BRD9 bromodomains [174].
BRD7/9	Unknown	VZ185 is a selective and rapid degrader of BRD9 and of its close homolog BRD7 [175].
BRD7/9	Unknown	GSK6776 as a soluble and selective BRD7/9 inhibitor [176].
BRD9	AML xenograft model	BI-7273 and BI-956456 are potent and selective BRD9 bromodomain inhibitors [177].
BRD9	Unknown	GNE-375 is a small-molecule inhibitor of the BRD9 bromodomain [178].
BRD9	Human AML	I-BRD9 is BRD9 bromodomain inhibitor [179].
BRD9	Human AML	Compound dBRD9 bridges the BRD9 bromodomain and the E3 ubiquitin ligase complex for degradation [180].
BPTF	Breast cancer cells	Compound BZ1 targets the BPTF bromodomain [181].
BPTF	Lung cancer cells	Compounds Cpd8 and Cpd10 are highly potent and selective inhibitors of the BPTF bromodomain [22].